Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-45S3
Application #
8138158
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2012-12-31
Budget Start
2010-09-02
Budget End
2010-12-31
Support Year
45
Fiscal Year
2010
Total Cost
$49,483
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Seo, S K; Gedrimaite, Z; Paskovaty, A et al. (2018) Impact of QuickFISH in addition to antimicrobial stewardship on vancomycin use and resource utilization in cancer patients with coagulase-negative staphylococcal blood cultures. Clin Microbiol Infect 24:1339.e7-1339.e12
McDuff, Susan G R; Chen, Ming-Hui; Renshaw, Andrew A et al. (2018) Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer 124:1391-1399
Sigel, Carlie S; Krauss Silva, Vitor Werneck; Reid, Michelle D et al. (2018) Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study. Cancer Cytopathol 126:326-335
Fanale, Michelle A; Horwitz, Steven M; Forero-Torres, Andres et al. (2018) Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood 131:2120-2124
Barzilai, Ori; DiStefano, Natalie; Lis, Eric et al. (2018) Safety and utility of kyphoplasty prior to spine stereotactic radiosurgery for metastatic tumors: a clinical and dosimetric analysis. J Neurosurg Spine 28:72-78
Rosenberg, Jonathan B; Kaplitt, Michael G; De, Bishnu P et al. (2018) AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Hum Gene Ther Clin Dev 29:24-47
Ma, Jennifer; Lok, Benjamin H; Zong, Jingfeng et al. (2018) Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. Int J Part Ther 4:10-19
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Garg, Angad; Goldgur, Yehuda; Schwer, Beate et al. (2018) Distinctive structural basis for DNA recognition by the fission yeast Zn2Cys6 transcription factor Pho7 and its role in phosphate homeostasis. Nucleic Acids Res 46:11262-11273
Scordo, Michael; Shah, Gunjan L; Kosuri, Satyajit et al. (2018) Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 24:133-141

Showing the most recent 10 out of 8799 publications